NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No. 188; Human growth hormone (somatropin) for the treatment of growth failure in children (review)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Manufacturers/sponsors	General
Ferring (somatropin)	Allied Health Professionals Federation
Ipsen (somatropin)	Board of Community Health Councils in
Lilly (somatropin)	Wales
 Merck Serono (somatropin) 	British National Formulary
 Novo Nordisk (somatropin) 	Care Quality Commission
Pfizer (somatropin)	Commissioning Support Appraisals
Sandoz (somatropin)	Service
	Department of Health, Social Services
Patient/carer groups	and Public Safety for Northern Ireland
Action for Children	Healthcare Improvement Scotland
Action for Sick Children	Medicines and Healthcare Products
Afiya Trust	Regulatory Agency
Black Health Agency	National Association of Primary Care
Child Growth Foundation	National Pharmacy Association
Children's Society	NHS Alliance
Equalities National Council	NHS Commercial Medicines Unit
Independent Age	NHS Confederation
Muslim Council of Britain	Public Health Wales NHS Trust
Muslim Health Network	Scottish Medicines Consortium
National Children's Bureau	
 National Parent Partnership Network 	Comparator manufacturers
Pituitary Foundation	None
 South Asian Health Foundation 	
Specialised Healthcare Alliance	Relevant research groups
 Turner Syndrome Support Society 	Cochrane Metabolic & Endocrine Discrete Cochrane October O
WellChild	Disorders Group
	Health Research Authority MDC Oliving Land Land
Professional groups	MRC Clinical Trials Unit
British Society for Paediatric	National Institute for Health Research
Endocrinology & Diabetes	Assessment Croun
Royal College of General Practitioners	Assessment Group
Royal College of Nursing	Assessment Group tbc Netional Institute for Health Basesrah
Royal College of Paediatrics & Child	National Institute for Health Research Health Tachnology Assessment
Health	Health Technology Assessment
Royal College of Pathologists	Programme
Royal College of Physicians	

National Institute for Health and Care Excellence

NICE Technology Appraisal No. 188; Human growth hormone (somatropin) for the treatment of growth

failure in children (review) Issue date: May 2013

- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- United Kingdom Clinical Pharmacy Association

Others

- Department of Health
- NHS England
- NHS Medway CCG
- NHS Wokingham CCG
- Welsh Government

<u>Associated Guideline Groups</u>

None

Associated Public Health Groups

None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: May 2013 Page 2 of 2

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.